Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials
Key CMC achievements advance EB-003 on the path to first-in-human trials CAMBRIDGE, Mass. — Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiat
(Financial Post, 2025-10-02T12:51:37Z)